Skip to content
logo MSD Oncology Clinical Trials
  • Início
  • Estudos
    • Menu principal
    • Visão geral do teste
    • Bexiga
    • Cabeça e Pescoço
    • Colorretal
    • Esofágico
    • Fígado e via Biliar
    • Gástrico
    • Ginecológico
    • Hematológico
    • Mama
    • Melanoma
    • Pediátrico
    • Próstata
    • Pulmão
    • Rim
    • Tumores Sólidos
  • Sobre
  • Perguntas frequentes
  • Para Profissionais Da Saúde
  • Português (BR)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Study Keyword: Programmed Cell Death 1 Ligand 1

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

Study Keyword: Programmed Cell Death 1 Ligand 1

Pembrolizumab as First-line Therapy for Advanced Merkel Cell Carcinoma

March 10, 2022

By clique_admin

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.

March 10, 2022

By clique_admin

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy

Estudo de pembrolizumabe mais docetaxel versus placebo mais docetaxel em câncer de próstata metastático resistente à castração sem tratamento anterior com quimioterapia

March 7, 2022

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

Estudo de pembrolizumabe mais olaparibe versus acetato de abiraterona ou enzalutamida em câncer de próstata metastático resistente à castração

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5′-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants

Coformulação de pembrolizumabe/vibostolimabe versus monoterapia com pembrolizumabe para câncer de pulmão de não pequenas células metastático positivo para ligante 1 de morte programada de células 1

March 7, 2022

By Support_Clique

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion

Estudo de pembrolizumabe em adultos com carcinoma cutâneo de células escamosas recorrente/metastático ou CcCE localmente avançado não ressecável

March 7, 2022

By Support_Clique

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA)

Segurança e eficácia de pembrolizumabe comparado ao placebo em melanoma ressecado de alto risco estágio II

March 7, 2022

By clique_admin

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either

logo-white MSD Oncology Clinical Trials
  • Política de privacidade MSD
  • Termos de uso
  • Preferências de cookies
  • Acessibilidade

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Acessibilidade

Acessibilidade